As of August 2026, the FDA has cleared four dental technologies that collectively reshape how clinicians image, diagnose, and plan treatment. These are not incremental updates to existing devices — they represent category-creating shifts in how dental data is captured and interpreted. For Canadian dental professionals watching the regulatory pipeline, each clearance signals a technology trajectory that will eventually cross the border.
1. MAGNETOM Free.Max Dental Edition: The First Dental-Dedicated MRI
On March 9, 2026, Dentsply Sirona and Siemens Healthineers received FDA clearance for the MAGNETOM Free.Max Dental Edition — the first MRI system designed specifically for dental applications. This is not a repurposed medical MRI with a dental coil bolted on. It is a purpose-built unit with a dedicated dental coil and specialized imaging software optimized for the oral cavity.
The clinical implications are significant. Unlike cone-beam computed tomography (CBCT), MRI produces zero ionizing radiation, making it suitable for repeated imaging sessions — particularly valuable in pediatric patients, pregnant individuals, and cases requiring longitudinal monitoring. Average scan time sits under 20 minutes.
What It Actually Shows
The system differentiates active inflammation from healthy tissue and scar tissue — a distinction that conventional dental radiography cannot reliably make. It assesses tooth pulp vitality non-invasively, visualizes teeth alongside adjacent structures and nearby nerves, and provides advanced soft-tissue contrast that CBCT cannot match.
Target applications include endodontics (pulp vitality assessment without cold testing or electric pulp testing), periodontics (soft-tissue inflammation mapping), orthodontics (root resorption monitoring without cumulative radiation dose), and TMJ disorder evaluation.
Pro Tip: If your practice currently refers patients to hospital-based MRI for TMJ or complex endodontic evaluation, monitor the rollout of dental-dedicated MRI at academic centres. Early adoption is most likely through university teaching hospitals and large multi-specialty clinics with the capital for a dedicated imaging suite.
Practical Considerations for Canadian Practices
The MAGNETOM Free.Max Dental Edition is currently cleared by the FDA for the U.S. market. Canadian practices should confirm Health Canada registration status before pursuing acquisition. The unit footprint and capital cost position it primarily for hospitals, university dental faculties (such as the University of Toronto Faculty of Dentistry), and large group practices — not solo operatories. However, the technology trajectory matters: as dental MRI matures, smaller and more affordable systems will follow, much as CBCT moved from hospital radiology suites to private practices over the past two decades.
2. CEPHX3D: Orthodontic AI Gets 3D Capability
On March 24, 2026, Orca Dental AI received FDA clearance for CEPHX3D, extending its orthodontic AI diagnostic platform from 2D cephalometric analysis to full 3D CBCT imaging. This makes CEPHX the only orthodontic AI platform with FDA clearance for both 2D and 3D modalities.
For orthodontic practices, the practical impact is workflow consolidation. Rather than switching between separate 2D and 3D analysis tools — each with its own interface, landmark conventions, and output formats — CEPHX3D provides a unified diagnostic environment. Automated 3D landmark identification reduces the manual annotation burden that currently makes CBCT-based treatment planning time-intensive.
Pro Tip: If your orthodontic practice already uses CBCT and spends significant chair-side or staff time on manual 3D cephalometric analysis, evaluate AI-assisted platforms that automate landmark identification. The time savings compound across high-volume practices.
3. 3Shape Dx Software: AI-Assisted Intraoral Scan Analysis
On April 28, 2026, 3Shape received FDA clearance for its Dx Software — an AI-assisted diagnostic tool that integrates with the company's TRIOS 6 intraoral scanner. The software comes in two tiers: Dx Plus and Dx Standard.
The system detects caries, plaque accumulation, tooth wear, and gingival recession directly from TRIOS 6 scans. It also generates patient education visuals and tracks changes over time — enabling longitudinal monitoring of conditions that currently rely on subjective clinical assessment and inconsistent chart notes.
Why This Matters for Practice Workflow
The integration of diagnostic AI directly into the intraoral scanning workflow is significant because it eliminates the need for a separate diagnostic step. The scanner simultaneously captures the digital impression (for restorative or orthodontic planning) and performs an AI-assisted diagnostic assessment. This is the kind of workflow integration that drives actual adoption — clinicians do not need to add a step or learn a new tool.
For practices that already own TRIOS 6 scanners, the Dx Software represents a software upgrade rather than a hardware purchase. For practices evaluating scanner purchases, the diagnostic AI capability becomes a meaningful differentiator in the competitive scanner market.
4. Smart View – Detect: AI for Periapical Pathology on CBCT
On May 4, 2026, Dentsply Sirona received FDA clearance for Smart View – Detect, an AI tool that identifies periapical radiolucencies on CBCT scans. According to Dentsply Sirona, internal studies showed approximately a 46 per cent relative increase in tooth-level detection sensitivity compared to unaided radiologist review, without increasing false positive rates.
Periapical radiolucencies — indicators of infection, cysts, or granulomas at the tooth apex — are among the most commonly missed findings on CBCT scans, particularly when they are small, located in regions with complex anatomy, or when the clinician is focused on a different diagnostic question (such as implant planning). An AI second reader that flags these findings regardless of the scan's primary indication addresses a genuine gap in diagnostic thoroughness.
Pro Tip: If your practice uses CBCT primarily for implant planning or third molar assessment, consider that AI-assisted pathology detection adds diagnostic value to scans you are already acquiring — turning single-purpose imaging into comprehensive diagnostic events.
The Bigger Picture: What These Four Clearances Signal
Taken together, these clearances reflect three converging trends in dental technology:
- Radiation reduction: Dental MRI offers zero-dose imaging for soft-tissue evaluation. As radiation awareness increases among patients and regulators, non-ionizing alternatives will gain traction, particularly in pediatric and orthodontic monitoring.
- AI as diagnostic co-pilot: Three of the four clearances are AI-powered diagnostic tools. The FDA is increasingly comfortable clearing AI that assists — rather than replaces — clinical judgment. For Canadian practices, this signals that Health Canada will face similar regulatory questions in the near future.
- Workflow integration over standalone tools: 3Shape's scanner-integrated diagnostics and Dentsply's CBCT-integrated pathology detection both embed AI into existing clinical workflows rather than requiring new equipment or separate software. This approach drives adoption because it reduces friction.
What Canadian Practices Should Do Now
These FDA clearances do not automatically translate to Canadian market availability. Health Canada maintains its own regulatory pathway for medical devices, and clearance timelines vary. However, Canadian dental professionals should take several preparatory steps:
- Track Health Canada's Medical Device Active Licence Listing (MDALL) for these products. FDA clearance often precedes Health Canada licensing by 6 to 18 months for dental devices from major manufacturers.
- Evaluate your existing imaging and diagnostic workflows for integration readiness. Practices already using CBCT can assess whether AI-assisted pathology detection would add value to their existing scan volume. Practices using TRIOS scanners should monitor 3Shape's Canadian rollout of Dx Software.
- Budget for software, not just hardware. Three of these four clearances are software-based — AI diagnostic platforms that overlay on existing imaging hardware. The capital cost of adding AI-assisted diagnostics may be significantly lower than purchasing new imaging equipment.
- Discuss AI-assisted diagnostics with your liability insurer. As AI tools become part of diagnostic workflows, professional liability considerations evolve. Understanding your insurer's position before adoption is prudent.
EBIKO Dental will continue monitoring Health Canada registrations and availability of these technologies for the Canadian dental market.
Frequently Asked Questions
Q: Are these FDA-cleared dental AI tools available in Canada?
FDA clearance does not grant Canadian market access. Each device must receive separate Health Canada authorization through the Medical Device licensing process. Canadian dental professionals should check the Medical Device Active Licence Listing (MDALL) database for current registration status before purchasing any of these technologies. Major manufacturers typically pursue Health Canada licensing within 6 to 18 months of FDA clearance.
Q: How does dental MRI compare to CBCT for everyday dental imaging?
Dental MRI excels at soft-tissue visualization — pulp vitality assessment, inflammation mapping, and TMJ evaluation — without any radiation exposure. CBCT remains superior for hard-tissue visualization, implant planning, and bone assessment. The two modalities are complementary rather than competitive. For most general practices, CBCT will remain the primary 3D imaging tool, while dental MRI will serve specialized diagnostic roles primarily in academic and large multi-specialty settings.
Q: Will AI diagnostic tools replace the need for clinical judgment in dental practice?
No. All four FDA clearances position AI as a diagnostic assistant — a second reader that flags findings for clinician review rather than making autonomous treatment decisions. The clinical responsibility for diagnosis and treatment planning remains with the licensed dental professional. AI tools are designed to increase detection sensitivity and reduce missed findings, not to replace the trained clinician's judgment.